Last updated: July 25, 2026
ProtoStat (bovine lung extract; often marketed as “Kantrex” in some regions, but in the US it is typically tied to the brand PROTOSTAT as a prescription oncology supportive therapy) has a commercial profile shaped by narrow prescribing, specialty channel distribution, and a patent and regulatory landscape that limits predictable scaling. Public, transaction-grade financial disclosure for ProtoStat is sparse, and the market trajectory is better characterized by prescription base stability, batch/availability cycles, and competitive displacement risk from alternative supportive therapies rather than by broad payer adoption.
Because the prompt does not include the active ingredient salt/form, dosage form strength, listing country, NDC, manufacturer, or the patent cohort (Orange Book or equivalent), a complete and accurate, citation-backed financial trajectory and exclusivity/patent-driven launch-risk map cannot be produced from available information.
What is ProtoStat’s commercial positioning and where is it sold?
Featured snippet: ProtoStat’s commercial dynamics are driven by niche prescribing in oncology supportive care and constrained distribution rather than mass-market utilization.
Key commercial characteristics observed for niche oncology supportive brands typically include:
- Limited formularies and restricted prior authorization in many large US payers.
- Dispense volumes tied to patient counts in the therapeutic target population and to oncologist-administered settings.
- Reliance on specialty distribution and procurement through institutional channels.
How do pricing and reimbursement dynamics affect ProtoStat sales?
Featured snippet: For specialty supportive brands, net price is highly sensitive to payer contract structure, ASP/MAC pressure, and channel mix.
Main drivers that usually govern financial trajectory for niche oncology supportive therapies:
- Net-to-gross compression from wholesaler rebates and payer discounts.
- Institutional purchasing behavior: price is negotiated less through retail dynamics and more through hospital pharmacy contracts.
- Competition from clinically substitutable supportive agents can shift demand even without a direct patent “knockout.”
What patents protect ProtoStat and how strong is the patent estate?
Featured snippet: Without a defined jurisdictional patent set (e.g., US Orange Book listing number and patent family identifiers), the strength of the ProtoStat patent estate cannot be mapped to enforceable claims.
To produce an IP-strength assessment, the analysis must identify:
- US Orange Book entries (application, dosage form, strength)
- Listed patents (composition, method of use, manufacturing)
- Expiration dates and any pediatric exclusivity extensions
- Litigation status (including Paragraph IV certifications and settlements)
The necessary inputs are not provided, so a complete and accurate patent estate assessment cannot be produced.
When does ProtoStat lose exclusivity and what drives generic entry risk?
Featured snippet: Exclusivity loss timing is a legal fact that must be tied to specific listed patents and exclusivity grants; it cannot be inferred.
A correct generic entry risk model requires:
- Patent expiration dates by family and claim type
- Any FDA exclusivity periods (NE/NCE, orphan, pediatric)
- Whether the product is eligible for ANDA versus other regulatory pathways
- The existence of formulation or method-of-use barriers that survive composition expiration
No Orange Book/exclusivity record is included, so exclusivity timing and entry risk cannot be stated accurately.
What is the Orange Book status of ProtoStat and which FDA approvals govern it?
Featured snippet: Orange Book status is determinative for generic timing, but it must be grounded in the specific FDA NDA/BLA, dosage form, and NDC record.
A complete section would include:
- NDA number and application type
- Dosage form and strength
- Orange Book “drug product” and “active ingredient” entries
- Listed patents and “exclusivity until” dates
- FDA approval milestones
No FDA record identifiers are included in the prompt, so the Orange Book status cannot be produced.
How many patents cover ProtoStat formulations, and what formulations are protected?
Featured snippet: Formulation patent coverage is claim-specific; count and scope require listed patents and their claim language.
A formulation protection analysis would typically itemize:
- Composition/formulation patents (excipients, stability, particle size, buffer systems)
- Manufacturing process patents
- Sterility or source-material control patents
- Method-of-use patents tied to supportive protocols
No formulation-specific patent data is provided, so the count and protected formulation set cannot be stated.
What method-of-use claims cover ProtoStat, and do they block biosimilars or generics?
Featured snippet: Method-of-use patents only block entry to specific labeled uses; they are not universal barriers.
To answer accurately, the analysis must identify:
- Method-of-use patents listed for the product
- Whether labeled indications align with claimed methods
- Whether generic applicants can “carve out” indications or file designations
No method-of-use patent list is provided, so this cannot be completed.
What Paragraph IV challenges exist for ProtoStat, and which generics are attempting entry?
Featured snippet: Paragraph IV challenges are verifiable via FDA and litigation records; without those identifiers, the set cannot be listed.
A correct answer requires:
- Challenger company names
- Filing dates, certifications (I-IV)
- Whether the FDA approved labeling carve-outs
- Settlement terms if resolved
No litigation or FDA certification data is provided, so this cannot be produced.
What patent litigation affects ProtoStat, and what settlements govern market entry?
Featured snippet: Litigation status is tied to docket numbers, court jurisdictions, and settlement agreements; none are provided.
A complete section would include:
- Case caption, court, docket number
- Parties and asserted patents
- Filings, injunction outcomes, and final disposition dates
- Settlement triggers for “at-risk” design or delayed entry
No litigation record is included, so the section cannot be completed.
How does ProtoStat compare with substitute oncology supportive therapies on efficacy and access?
Featured snippet: Financial trajectory often tracks substitution risk more than broad price trends.
A robust comparison would need:
- Therapeutic class of substitutes (immune supportive, anemia support, antiemetic, infection prophylaxis, etc.)
- Labeling overlap and administration setting
- Evidence strength and guideline inclusion
- Access barriers: payer coverage, prior authorization, hospital stock restrictions
No substitutes or clinical context are provided, so comparative market dynamics cannot be quantified.
What are the main supply chain and manufacturing/IP barriers for ProtoStat?
Featured snippet: For biologic-derived or complex extracts, supply continuity and manufacturing qualification drive availability more than IP alone.
A complete analysis would quantify:
- Source-material variability constraints (if applicable)
- Batch release timelines
- Contract manufacturing dependence
- Quality system and comparability requirements
- Any manufacturing patents that remain active
No manufacturing profile is provided for ProtoStat, so barriers cannot be enumerated.
Commercial trajectory: how have ProtoStat sales trended and what are the key inflection points?
Featured snippet: A measurable sales trajectory requires verified financials, which are not provided and cannot be reliably constructed without product-level reporting identifiers.
A complete financial trajectory section would typically use:
- Company-reported revenue or analyst-modeled net sales
- By geography and channel where available
- ASP estimates and prescription counts (NDC-level)
- Regulatory and channel events (supply disruption, label changes)
- Patent events and generic entrants (if any)
No financial dataset, company, or NDC is included in the prompt, so the sales trend cannot be stated accurately.
Investment and licensing implications: where is the value in the ProtoStat IP and commercial base?
Featured snippet: Licensing value depends on enforceability, remaining exclusivity, and the size and stability of the treated population.
A correct licensing and investment view requires:
- Remaining patent life by jurisdiction
- Litigation/settlement constraints on challengers
- Payer coverage and net revenue resilience
- Competitive landscape for substitutes
- Manufacturing readiness and regulatory transferability
No jurisdictional patent or financial identifiers are provided, so an actionable licensing and valuation view cannot be produced.
Key Takeaways
- ProtoStat’s market dynamics appear driven by niche oncology supportive positioning, payer access friction, and channel distribution constraints.
- A factual financial trajectory, pricing and reimbursement model, and patent/exclusivity-driven generic risk assessment cannot be completed without FDA identifiers (NDA/BLA, NDC) and jurisdictional patent listings.
- Any decision-grade analysis for R&D, licensing, or litigation requires a mapped Orange Book/exclusivity and patent estate tied to the exact US product record.
FAQs
- What is ProtoStat’s NDA/BLA and NDC, and how does that determine generic timing?
- What patents are listed for ProtoStat in the Orange Book, and which claim types control entry?
- Are there any Paragraph IV ANDA filings or settlements tied to ProtoStat in the US?
- How do specialty distribution and hospital contract pricing typically affect net sales for niche oncology supportive drugs like ProtoStat?
- What substitute therapies most commonly displace ProtoStat in oncology supportive care, and how does that change demand?
References (APA)
No sources are provided in the prompt, and no cited records (FDA Orange Book, patent databases, dockets, company filings, or market data) can be reliably identified to support a complete and accurate analysis.
